Connection
Virginia Borges to Maximum Tolerated Dose
This is a "connection" page, showing publications Virginia Borges has written about Maximum Tolerated Dose.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.068 |
|
|
|
-
Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 07; 19(7):880-888.
Score: 0.036
-
Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jul 15; 23(14):3529-3536.
Score: 0.032